Bronchogenic Carcinoma Non-small cell Inoperable TNM clinical staging
Item
1. histologically or cytologically confirmed non-small cell bronchogenic carcinoma, inoperable stage iiib or iv
boolean
C0007121 (UMLS CUI [1,1])
C0445128 (UMLS CUI [1,2])
C0205187 (UMLS CUI [1,3])
C3258246 (UMLS CUI [1,4])
Age
Item
2. aged 18 years or older
boolean
C0001779 (UMLS CUI [1])
Prior Chemotherapy Platinum-Based failed
Item
3. failed previous platinum-based chemotherapy
boolean
C1514457 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
Measurable Disease Quantity | Measurable lesion Dimension Quantity CT | Measurable lesion Dimension Quantity Spiral CT
Item
4. presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as ≥ 20 mm with conventional ct or ≥ 10 mm with spiral ct scan
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0439534 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0040405 (UMLS CUI [2,4])
C1513041 (UMLS CUI [3,1])
C0439534 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0860888 (UMLS CUI [3,4])
ECOG performance status
Item
5. performance status of eastern cooperative oncology group (ecog) 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement
Item
6. white blood cell (wbc) ≥ 3,000/mm3, absolute neutrophil count (anc) ≥ 1,500/mm3, platelets ≥ 100,000/mm3 and hemoglobin ≥ 10 mg / dl
boolean
C0023508 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
Creatinine measurement, serum
Item
7. serum creatinine level 2.0 mg/dl or lower
boolean
C0201976 (UMLS CUI [1])
Serum total bilirubin measurement
Item
8. serum bilirubin less than 1.5 times the upper limit of normal range (uln)
boolean
C1278039 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Relationship Secondary malignant neoplasm of liver
Item
9. alanine aminotransferase (alt) or aspartate aminotransferase (ast) less than 3 times the uln (less than 5 times the uln in liver metastases)
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C0494165 (UMLS CUI [3,2])
Informed Consent | Childbearing Potential Contraceptive methods | Female Sterilization | Radiation | Menopause | Intrauterine Devices | Contraceptives, Oral | Contraception, Barrier | Operative Surgical Procedures Previous | Progressive Disease
Item
10. written informed consent to participate in the trial in addition, in female patient with childbearing potential, either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device [iud], birth control pills, or barrier device) during and for three months after trial. patients who previously treated by surgery are needed to demonstrate progressive disease before entering the study.
boolean
C0021430 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0015787 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
C0025320 (UMLS CUI [5])
C0021900 (UMLS CUI [6])
C0009905 (UMLS CUI [7])
C0004764 (UMLS CUI [8])
C0543467 (UMLS CUI [9,1])
C0205156 (UMLS CUI [9,2])
C1335499 (UMLS CUI [10])
Communicable Disease
Item
1. active infection (at the discretion of the investigator).
boolean
C0009450 (UMLS CUI [1])
CNS metastases
Item
2. active central nervous system (cns) metastases.
boolean
C0686377 (UMLS CUI [1])
Breast Feeding
Item
3. breast feeding.
boolean
C0006147 (UMLS CUI [1])
Comorbidity Systemic Serious | Comorbidity Inconsistent Clinical Trial
Item
4. serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
boolean
C0009488 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C0442809 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
Investigational New Drugs
Item
5. use of any investigational agent in the month before enrollment into the study.
boolean
C0013230 (UMLS CUI [1])
Therapeutic radiology procedure Myelosuppressive Target Lesion | Chemotherapy | Hormone Therapy | Immunotherapy
Item
6. concomitant myelosuppressive radiotherapy to target lesion, chemotherapy, hormonal therapy, or immunotherapy will not be allowed.
boolean
C1522449 (UMLS CUI [1,1])
C1513793 (UMLS CUI [1,2])
C2986546 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
C0279025 (UMLS CUI [3])
C0021083 (UMLS CUI [4])